Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T18:56:48.662Z.
Calculation as of: 2026-10-06T18:56:48.662Z.
Quote observation: 2026-10-06T18:54:52.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1e37222dd90dbab5e03bfa1bbf20eaf6e61690ec1e62f49524765e66f30de265
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Filana Therapeutics, Inc. (FLNA) | $40.49M | N/A | N/A | N/A | N/A |
| Veru Inc. (VERU)vs › | $40.05M | N/A | 6.82 | 20.88 | 41.23 |
| Metagenomi, Inc. Common Stock (MGX)vs › | $39.15M | 2.89 | 2.35 | 2.86 | 2.86 |
| Precipio, Inc. (PRPO)vs › | $41.95M | 1.53 | 1.75 | 1.06 | 1.68 |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.98M | 0.44 | 0.32 | 0.77 | 1.11 |
| Nephros, Inc. (NEPH)vs › | $38.11M | 1.84 | 2.43 | 1.99 | 2.26 |
| Nano-X Imaging Ltd. (NNOX)vs › | $42.93M | 2.75 | 11.52 | 28.84 | 51.10 |
| BioStem Technologies, Inc. (BSEM)vs › | $43.82M | N/A | 0.99 | 3.28 | 3.54 |
| Incannex Healthcare Limited (IXHL)vs › | $37.73M | N/A | N/A | N/A | N/A |
| Rapid Micro Biosystems, Inc. (RPID)vs › | $43.70M | 1.24 | 3.77 | 3.07 | 5.17 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-09-30 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-12 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-06-30 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
